Credence and Ceylinco team up to provide 99.7% accurate cancer diagnosis

Friday, 17 April 2015 03:27 - - {{hitsCtrl.values.hits}}

Credence and Ceylinco Healthcare, both leaders in cancer diagnostics and prevention, have collaborated to provide state-of-the-art prevention and screening services using pioneering products designed and developed by Credence Genomics, Sri Lanka’s first and only pioneering next generation sequencing facility. Ceylinco Healthcare service has been providing patient management and services for the last 15 years along with specialisation in oncology and treatment. The centre provides radiation treatment, chemotherapy, radioactive iodine treatment regimens, along with post treatment, follow-up and patient care. The collaboration with Credence enables Ceylinco Healthcare to provide diagnostics and prediction, which is 99.7% accurate for the first time in Sri Lanka. This will allow for timely diagnosis and treatment. Ceylinco Healthcare will also offer a test for precision medicine, which again is another unique offering from Credence Genomics. Other tests for post treatment patients are Bactfast and Fungifast identifying all known fungus and bacteria known to man.

Sri Lanka has a very high prevalence and incidence of cancer; hence services that provide accurate prediction and diagnostics of cancer allow individuals who are predisposed to cancer to avail themselves of early screening. This will improve quality of life and early intervention if needed, thus preventing development of late stage cancer. A team of counsellors are also available at Ceylinco Healthcare and Credence to advise you on the best test for you or your family. Ceylinco Healthcare Services owns and operates the state-of-the-art Ceylinco Radiation Treatment Centre and the Tomotherapy Centre at Park Street, Colombo 2. The Ceylinco Healthcare Centre and the Ceylinco Diabetes Centre, offers comprehensive screening, diagnostic services and medical care in a comfortable and non-hospital atmosphere. Further information could be obtained by calling the hotline – 0710380011.

Durdans Hospital and Credence Genomics in partnership

Durdans Hospital a premier tertiary healthcare service provider in Sri Lanka established since 1945 has partnered with Credence Genomics Ltd, Sri Lanka’s pioneering commercial next generation sequencing facility to provide preventive and diagnostic testing, based on the Credence Next Generation Sequencing (NGS) platform. The platform allows with 99.7% accuracy to predict and diagnose their patients in multiple specialties

not limited to, but including oncology, cardiology, immunology, paediatrics and infectious disease. Durdans Laboratory services has an island wide network of collection centres which can collect samples at any location in Sri Lanka and are centrally processed at its centre in Colombo. Credence Genomics is the only company in Sri Lanka to provide genomic diagnostics to their clients, while Durdans Hospital provides excellent healthcare services. With its experience in molecular diagnostics and existing DNA based test menu, the synergy between Credence and Durdans was a natural evolution bringing two pioneers in the industry together. Credence Genomics’ innovative test menu allows individuals to predict, diagnose and treat cancer, or inherited diseases based on gene expressions. The test allows premier healthcare providers like Durdans to monitor their patients closely, providing a better quality of life along with careful screening and treatment if applicable. Credence’s tests also play an active role in infectious patients – Bactfast and Fungifast which identify all known bacteria and fungus known to man in one test with the fastest turnarounds. The collaboration between Durdans and Credence allows Durdans to provide the latest technology and advances in NGS to all their patients using their existing services. To obtain further information, please call 0710380011.